2022-2023 Dosing Calendar Every 28 Days

2024-2025 Dosing Calendar | Every 28 Days1,*

Use this calendar to help schedule dosing and office appointments for your patients.

How to use the 28-day dosing calendar: ? Locate initial dosing date ? Move 1 box down (This will be 28 days later) ? Continue scheduling by moving down the same column

Key: Federal holidays in 2024-2025 Weekends in 2024-2025

M T W TH F S SU M T W TH F S SU M T W TH F S SU M T W TH F S SU

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL

29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

JUL JUL JUL AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG

26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

AUG AUG AUG AUG AUG AUG SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP

23 24 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

SEP SEP SEP SEP SEP SEP SEP SEP OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT

21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV

18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12

DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN

13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9

JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN FEB FEB FEB FEB FEB FEB FEB FEB FEB

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 1 2 3 4 5 6 7 8 9

FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB MAR MAR MAR MAR MAR MAR MAR MAR MAR

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6

MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR APR APR APR APR APR APR

7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4

APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR MAY MAY MAY MAY

5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1

MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY JUN

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN

30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

JUN JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL

*Patients should receive SYNAGIS? (palivizumab) every 28 to 30 days throughout the respiratory syncytial virus (RSV) season. This calendar has been provided as a guide only and is not intended to be a substitute for, or have an influence on, the independent medical judgment of the healthcare professional.

INDICATION SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: ? with a history of premature birth (35 weeks gestational age) and who are 6 months of age or younger at the beginning

of RSV season ? with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months

of age or younger at the beginning of RSV season ? with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning

of RSV season

LIMITATIONS OF USE The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease. CONTRAINDICATIONS Previous significant hypersensitivity reaction to SYNAGIS.

IMPORTANT SAFETY INFORMATION Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Please see additional Important Safety Information on the next page. Click here for full Prescribing Information for SYNAGIS, including Patient Information.

2024-2025 Dosing Calendar | Every 30 Days1,*

Use this calendar to help schedule dosing and office appointments for your patients.

How to use the 30-day dosing calendar: ? Locate initial dosing date ? Move 1 box down and 2 boxes to the right (This will be 30 days later) ? Continue scheduling by moving 1 box down and 2 boxes to the right

Key: Federal holidays in 2024-2025 Weekends in 2024-2025

M T W TH F S SU M T W TH F S SU M T W TH F S SU M T W TH F S SU

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL

29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

JUL JUL JUL AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG AUG

26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

AUG AUG AUG AUG AUG AUG SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP SEP

23 24 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

SEP SEP SEP SEP SEP SEP SEP SEP OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT

21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT OCT NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV

18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12

DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC DEC JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN

13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9

JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN JAN FEB FEB FEB FEB FEB FEB FEB FEB FEB

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 1 2 3 4 5 6 7 8 9

FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB FEB MAR MAR MAR MAR MAR MAR MAR MAR MAR

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6

MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR APR APR APR APR APR APR

7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4

APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR APR MAY MAY MAY MAY

5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1

MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY MAY JUN

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN JUN

30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

JUN JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL JUL

*Patients should receive SYNAGIS? (palivizumab) every 28 to 30 days throughout the RSV season. This calendar has been provided as a guide only and is not intended to be a substitute for, or have an influence on, the independent medical judgment of the healthcare professional.

IMPORTANT SAFETY INFORMATION (cont'd) Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder. RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays. Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions. Most Common Adverse Reactions: The most common adverse reactions are fever and rash. Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These are not all the possible risks associated with SYNAGIS. Please click here for full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

Reference: 1. SYNAGIS (palivizumab) [prescribing information]. Waltham, MA: Sobi, Inc. 2021.

SYNAGIS? is a registered trademark of Arexis AB c/o Swedish Orphan Biovitrum AB (publ) ?2024 Swedish Orphan Biovitrum. All rights reserved. PP-11003 (V6.0) 02/24

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download